Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Jul;39(5):e3632.
doi: 10.1002/dmrr.3632. Epub 2023 Mar 20.

Association of osteocalcin, osteoprotegerin, and osteopontin with cardiovascular disease and retinopathy in type 2 diabetes

Ernesto Maddaloni  1   2 , Lucia Coraggio  1 , Rocco Amendolara  1 , Marco G Baroni  3 , Maria G Cavallo  1 , Massimiliano Copetti  4 , Efisio Cossu  5 , Paola D'Angelo  6 , Luca D'Onofrio  1 , Salvatore De Cosmo  4 , Frida Leonetti  1 , Susanna Morano  1 , Lelio Morviducci  7 , Nicola Napoli  8 , Sabrina Prudente  4 , Giuseppe Pugliese  1 , Kyoungmin Park  9 , Rury R Holman  2 , Vincenzo Trischitta  1   4 , Raffaella Buzzetti  1 ; SUMMER Study in Diabetes Group
Collaborators, Affiliations

Association of osteocalcin, osteoprotegerin, and osteopontin with cardiovascular disease and retinopathy in type 2 diabetes

Ernesto Maddaloni et al. Diabetes Metab Res Rev. 2023 Jul.

Abstract

Background: Novel biomarkers of vascular disease in diabetes could help identify new mechanistic pathways. Osteocalcin, osteoprotegerin, and osteopontin are key molecules involved in bone and vascular calcification processes, both of which are compromised in diabetes. We aimed to evaluate possible associations of osteocalcin, osteoprotegerin, and osteopontin with cardiovascular disease (CVD) and diabetic retinopathy (DR) among people with type 2 diabetes (T2D).

Materials and methods: Osteocalcin, osteoprotegerin, and osteopontin concentrations were measured at enrolment in 848 participants with T2D from the Sapienza University Mortality and Morbidity Event Rate (SUMMER) Study (ClinicalTrials.gov: NCT02311244). Logistic regression models and propensity score matching were used to assess possible associations of osteocalcin, osteoprotegerin, and osteopontin with a history of CVD and with evidence of any grade of DR adjusting for confounders.

Results: Previous CVD was reported in 139 (16.4%) participants, while 144 (17.0%) had DR. After adjusting for possible confounders, osteocalcin but not osteoprotegerin or osteopontin concentrations were associated with a history of CVD (Odds Ratio [OR] and 95% CI for one standard deviation (SD) increase in osteocalcin concentrations (natural log): 1.35 (1.06-1.72), p = 0.014). Associations with prevalent DR were seen for osteoprotegerin (OR for one SD increase in osteoprotegerin concentrations (natural log): 1.25 (1.01-1.55), p = 0.047) and osteopontin (OR for one SD increase in osteopontin concentrations (natural log): 1.25 (1.02-1.53), p = 0.022), but not osteocalcin.

Conclusions: In T2D, higher serum osteocalcin concentrations are associated with macrovascular complications and higher osteoprotegerin and osteopontin concentrations with microvascular complications, suggesting that these osteokines might be involved in pathways directly related to vascular disease.

Keywords: biomarkers; bone-vascular axis; cardiovascular disease; diabetic retinopathy; osteokines; type 2 diabetes.

PubMed Disclaimer

References

REFERENCES

    1. Harding JL, Pavkov ME, Magliano DJ, Shaw JE, Gregg EW. Global trends in diabetes complications: a review of current evidence. Diabetologia. 2019;62(1):3-16. https://doi.org/10.1007/s00125-018-4711-2
    1. Dal Canto E, Ceriello A, Rydén L, et al. Diabetes as a cardiovascular risk factor: an overview of global trends of macro and micro vascular complications. Eur J Prev Cardiol. 2019;26(2_Suppl l):25-32. https://doi.org/10.1177/2047487319878371
    1. Lampropoulos CE, Papaioannou I, D’Cruz DP. Osteoporosis--a risk factor for cardiovascular disease? Nat Rev Rheumatol. 2012;8(10):587-598. https://doi.org/10.1038/nrrheum.2012.120
    1. D’Onofrio L, Maddaloni E, Buzzetti R. Osteocalcin and sclerostin: background characters or main actors in cardiovascular disease? Diabetes Metab Res Rev. 2020;36(1). https://doi.org/10.1002/DMRR.3217
    1. Rashdan NA, Sim AM, Cui L, et al. Osteocalcin regulates arterial calcification via altered wnt signaling and glucose metabolism. J Bone Min Res. 2020;35(2):357-367. https://doi.org/10.1002/JBMR.3888

Publication types

Associated data